P. van Riel

Abatacept (CTLA4Ig) treatment increases the remission rate in rheumatoid arthritis patients refractory to methotrexate treatment (2004)

Westhovens, R, Van Riel, P, Sibilia, J, Vratsanos, G, Nuamah, I, Becker, JC

No abstract available.

Proposal to establish a register for the long term surveillance of adverse events in patients with rheumatic diseases exposed to biological agents: the EULAR Surveillance Register for Biological Compounds

SILMAN, A., KLARESKOG, L., BREEDVELD, F., BRESNIHAN, B., MAINI, R., VAN RIEL, P., ...

Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology

Buttgereit, F, Da Silva, J A P, Boers, M, Burmester, G, Cutolo, M, Jacobs, J, ...

In rheumatology and other medical specialties there is a discrepancy between the widespread use and the imprecise designation of glucocorticoid treatment regimens. Verbal descriptions of...

EULAR Standing Committee on International Clinical Studies Including Therapeutic Trials (ESCISIT)

Van Riel, P

When a DMARD fails, should patients switch to sulfasalazine or add sulfasalazine to continuing leflunomide?

Dougados, M, Emery, P, Lemmel, E, Zerbini, C, Brin, S, Van Riel, P

Objective: To evaluate the efficacy and safety of adding sulfasalazine to leflunomide treatment compared with switching to sulfasalazine alone in patients with RA with an inadequate response to...